On June 2, 2026 AvenCell Therapeutics, a clinical-stage cell therapy company developing switchable CAR-T therapies for cancer, reported that data from the completed Phase 1a portion of the RevSTAR-123 study, evaluating AvenCell’s investigational switchable allogeneic CAR-T candidate (AVC-201) in patients with CD123-positive relapsed/refractory (r/r) or minimal residual disease (MRD) positive acute myeloid leukemia (AML), will be presented in a late-breaking oral presentation in the plenary session at the 2026 European Hematology Association (EHA) (Free EHA Whitepaper) Congress, taking place June 11-14 in Stockholm, Sweden. The study is registered at ClinicalTrials.gov as NCT05949125.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
EHA 2026 Abstract Details
Abstract number
EHA-7241
Title
First-in-class Switchable Allogeneic CAR-T therapy for
CD123+ AML – Results from the Phase Ia RevSTAR-
123 (AVC-201-01) Study
Topic
Gene therapy, cellular immunotherapy and vaccination
– Clinical
Presenter
Martin Wermke, University Hospital Carl Gustav Carus
Dresden
Presentation details
Plenary Abstracts Session on Saturday, June 13, 12:00
– 13:30 CEST
(Press release, AvenCell Therapeutics, JUN 2, 2026, View Source [SID1234666384])